<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Yamamoto JK</submitter><funding>NIAID NIH HHS</funding><pagination>14-25</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC3721975</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>8(1)</volume><pubmed_abstract>Feline immunodeficiency virus (FIV) discovered in 1986 is a lentivirus that causes AIDS in domestic cats. FIV is classified into five subtypes (A-E), and all subtypes and circulating intersubtype recombinants have been identified throughout the world. A commercial FIV vaccine, consisting of inactivated subtype-A and -D viruses (Fel-O-Vax FIV, Fort Dodge Animal Health), was released in the United States in 2002. The United States Department of Agriculture approved the commercial release of Fel-O-Vax FIV based on two efficacy trials using 105 laboratory cats and a major safety trial performed on 689 pet cats. The prototype and commercial FIV vaccines had broad prophylactic efficacy against global FIV subtypes and circulating intersubtype recombinants. The mechanisms of cross-subtype efficacy</pubmed_abstract><journal>Current HIV research</journal><pubmed_title>Feline immunodeficiency virus model for designing HIV/AIDS vaccines.</pubmed_title><pmcid>PMC3721975</pmcid><funding_grant_id>R01 AI030904</funding_grant_id><funding_grant_id>R01 AI065276</funding_grant_id><funding_grant_id>R01-AI065276</funding_grant_id><funding_grant_id>R01-AI030904</funding_grant_id><pubmed_authors>Sanou MP</pubmed_authors><pubmed_authors>Yamamoto JK</pubmed_authors><pubmed_authors>Abbott JR</pubmed_authors><pubmed_authors>Coleman JK</pubmed_authors></additional><is_claimable>false</is_claimable><name>Feline immunodeficiency virus model for designing HIV/AIDS vaccines.</name><description>Feline immunodeficiency virus (FIV) discovered in 1986 is a lentivirus that causes AIDS in domestic cats. FIV is classified into five subtypes (A-E), and all subtypes and circulating intersubtype recombinants have been identified throughout the world. A commercial FIV vaccine, consisting of inactivated subtype-A and -D viruses (Fel-O-Vax FIV, Fort Dodge Animal Health), was released in the United States in 2002. The United States Department of Agriculture approved the commercial release of Fel-O-Vax FIV based on two efficacy trials using 105 laboratory cats and a major safety trial performed on 689 pet cats. The prototype and commercial FIV vaccines had broad prophylactic efficacy against global FIV subtypes and circulating intersubtype recombinants. The mechanisms of cross-subtype efficacy</description><dates><release>2010-01-01T00:00:00Z</release><publication>2010 Jan</publication><modification>2025-04-26T10:57:30.675Z</modification><creation>2019-06-05T18:58:15Z</creation></dates><accession>S-EPMC3721975</accession><cross_references><pubmed>20210778</pubmed><doi>10.2174/157016210790416361</doi></cross_references></HashMap>